Alto Neuroscience, Inc. - 10-Q Filing
Alto Neuroscience filed its quarterly report for the period ended March 31, 2026. The filing includes financial data related to research and development expenses of $48 million and general and administrative expenses of $15 million during Q1 2026.
Tickers: $ANRO